<DOC>
	<DOCNO>NCT02839460</DOCNO>
	<brief_summary>This single center , prospective biomarker study evaluate serum level TWEAK expression level TWEAK Fn14 muscle biopsy patient sarcopenia well healthy , physically active control .</brief_summary>
	<brief_title>A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>To eligible participate study , candidate must meet following eligibility criterion Baseline time point specify individual eligibility criterion list : All Participants 1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information accordance national local subject privacy regulation Subjects Sarcopenia 1 . Men postmenopausal woman 65 year age old 2 . Gait speed measure 4 meter &lt; 1.0 m/s OR grip strength &lt; 26 kg men &lt; 16 kg woman . 3 . Appendicular skeletal muscle adjust BMI DXA ≤ 0.789 men ≤ 0.512 woman . 4 . Weigh least 40kg ; 5 . Selfreported difficulty climb 10 step OR walk outside level ground 1/4 mile Healthy Controls 1 . Men postmenopausal woman 65 Years age old 2 . Body mass index ( BMI ) 18.5 30 kg/m2 inclusive time Screening 3 . Measures Physical Performance Lean Mass exceed threshold define Sarcopenia group . 4 . ≥ 150 minutes/week moderateintensity physical activity OR regular engagement resistance training ≥ 2 days/week 5 . Willing maintain consistent diet pattern physical activity duration study Candidates exclude study entry follow exclusion criterion exist Screening : 1 . History human immunodeficiency virus ( HIV ) , hepatitis B C , tuberculosis ( TB ) 2 . Immunocompromized subject , determine Investigator , base medical history , physical examination , laboratory testing , due prior current immunosuppressive immunomodulating treatment , include , limited , HIV infection , history organ transplantation , antirejection therapy 3 . Acute infection ( urinary , respiratory , ) within past week hospitalization within one month 4 . Participation interventional clinical study within 12 week 5 . A low limb fracture past 6 month impairment disease severely affect gait ( e.g . stroke hemiparesis , myasthenia gravis , Parkinson 's disease , peripheral polyneuropathy , intermittent claudication advance peripheral vascular disease , spinal stenosis , severe osteoarthritis knee hip ) ; 6 . Any underlying muscle disease include active myopathy muscular dystrophy . 7 . Confirmed diagnosis heart failure classify New York Heart Association Class III IV ( e.g . cardiomyopathy ) hypertrophic cardiomyopathy . 8 . Type I diabetes uncontrolled Type 2 diabetes ( HA1C ≥ 9 ) . 9 . Requires regular assistance another person general activity daily live ( e.g . bathing , dress ) 10 . Moderate Vigorous Exercise perform week prior study visit ( temporary exclusion reschedule ) 11 . Any condition judge Principal Investigator Study Physician preclude safe participation study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>